There have been major advances in the armamentarium for hepatocellular carcinoma
(HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and …

Hepatocellular carcinoma (HCC) mortality rates are increasing globally, and particularly in
the Western world. Cirrhosis remains the predominant risk factor for HCC. However …

This guidance document provides an updated approach to the prevention, diagnosis, and
treatment of hepatocellular carcinoma (HCC). The prior American Association for the Study …

The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging,
treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and …

Abstract The Clinical Practice Manual for Hepatocellular Carcinoma was published based
on evidence confirmed by the Evidence-based Clinical Practice Guidelines for …

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality and
has an increasing incidence worldwide. Locoregional therapies, defined as imaging-guided …

PURPOSE In a previous phase II trial, hepatic arterial infusion chemotherapy (HAIC) with
infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) yielded higher treatment …

Background Transarterial chemoembolization (TACE) is the recommended treatment for
intermediate hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver …

The incidence of hepatocellular carcinoma (HCC) has been rising worldwide over the last
20 years and is expected to increase until 2030 in some countries including the United …

Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage
hepatocellular carcinoma (HCC). In this review, we summarize recent updates on the use of …